Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Investing Activities (2016 - 2025)

Ptc Therapeutics has reported Cash from Investing Activities over the past 14 years, most recently at $34.0 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $34.0 million for Q4 2025, down 87.3% from a year ago — trailing twelve months through Dec 2025 was -$862.0 million (down 2050.98% YoY), and the annual figure for FY2025 was -$862.0 million, down 2050.98%.
  • Cash from Investing Activities for Q4 2025 was $34.0 million at Ptc Therapeutics, up from -$289.6 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for PTCT hit a ceiling of $267.7 million in Q4 2024 and a floor of -$422.0 million in Q2 2025.
  • Median Cash from Investing Activities over the past 5 years was $3.2 million (2021), compared with a mean of -$24.3 million.
  • Biggest five-year swings in Cash from Investing Activities: soared 383.54% in 2024 and later plummeted 578.67% in 2025.
  • Ptc Therapeutics' Cash from Investing Activities stood at $68.3 million in 2021, then plummeted by 52.49% to $32.4 million in 2022, then plummeted by 391.06% to -$94.4 million in 2023, then soared by 383.54% to $267.7 million in 2024, then crashed by 87.3% to $34.0 million in 2025.
  • The last three reported values for Cash from Investing Activities were $34.0 million (Q4 2025), -$289.6 million (Q3 2025), and -$422.0 million (Q2 2025) per Business Quant data.